Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo - 16/06/19
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 10 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | A RGD conjugated, pH sensitive lipid was synthesized. |
• | A RGD modified, DOX loaded SLNs was constructed. |
• | RGD-DOX-SLNs could improve breast cancer therapy. |
Abstract |
Breast cancer is the leading cause of cancer mortality in women worldwide. To overcome the toxic side effects and multidrug resistance (MDR) during doxorubicin (DOX) chemotherapy, an arginine-glycine-aspartic (RGD) tripeptide modified, pH-sensitive solid lipid nanoparticles (SLNs) is employed in this study. In this study, a RGD conjugated, pH sensitive lipid was synthesized using glycerin monostearate (GMS) and adipic acid dihydrazide (HZ) as lipid materials and named RGD-HZ-GMS. RGD-HZ-GMS was applied to encapsulate DOX to construct a RGD modified, DOX loaded SLNs (RGD-DOX-SLNs). To evaluate the anticancer effect of RGD-DOX-SLNs, breast cancer cell line (MCF-7 cells) and DOX resistant cell line (MCF-7/ADR cells) were used. in vivo tumor suspension and toxicity effects were evaluated on mice bearing MCF-7/ADR cells breast cancer model. RGD-DOX-SLNs had a uniformly spherical shape. The mean particle size and zeta potential of the RGD-DOX-SLNs was 96.3 nm and 35.6 mV, respectively. RGD-DOX-SLNs showed 5.58 fold higher area under the plasma concentration – time curve (AUC) compared with DOX solution. Terminal half life (T1/2) and peak concentration (Cmax) of RGD-DOX-SLNs was 10.85 h and 39.12 ± 2.71 L/kg/h. in vitro and in vivo antitumor results indicate that RGD-DOX-SLNs might be a promising novel lipid carrier which could improve breast cancer therapy.
Le texte complet de cet article est disponible en PDF.Keywords : Breast cancer, Arginine-glycine-aspartic tripeptide, pH sensitive, Solid lipid nanoparticles, Doxorubicin
Plan
Vol 116
Article 109006- août 2019 Retour au numéro
Article précédent
- IGFBPrP1 accelerates autophagy and activation of hepatic stellate cells via mutual regulation between H19 and PI3K/AKT/mTOR pathway
- Ting-Juan Huang, Jun-Jie Ren, Qian-Qian Zhang, Yang-Yang Kong, Hai-Yan Zhang, Xiao-Hong Guo, Hui-Qin Fan, Li-Xin Liu
- Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis
- Shi-Jun Yue, Juan Liu, Wen-Xiao Wang, Ai-Ting Wang, Xin-Yu Yang, Hua-Shi Guan, Chang-Yun Wang, Dan Yan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?